18 and older, any sex, with Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percentage of Participants With Treatment Success at Week 8Primary· Week 8
Treatment success defined as at least a 2-grade improvement from Baseline in the IGA score and an IGA score equating to "clear" or "almost clear" at Week 8. The IGA score was based on a 5-point scale ranging from 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe). The face, scalp, palms, soles, axillae, and intertriginous areas were excluded from this assessment.
Group
Value
95% CI
IDP-122 Lotion
36.5
IDP-122 Vehicle Lotion
8.13
Percentage of Participants With Treatment Success at Weeks 2, 4, 6, and 12Secondary· Weeks 2, 4, 6, and 12 (4-week follow-up)
Treatment success defined as at least a 2-grade improvement from Baseline in the Investigator's Global Assessment (IGA) score and an IGA score equating to "clear" or "almost clear" at Weeks 2, 4, 6, and 12. The IGA score was based on a 5-point scale ranging from 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe). The face, scalp, palms, soles, axillae, and intertriginous areas were excluded from this assessment.
Week 2
Group
Value
95% CI
IDP-122 Lotion
7.06
IDP-122 Vehicle Lotion
0
Week 4
Group
Value
95% CI
IDP-122 Lotion
19.81
IDP-122 Vehicle Lotion
2.77
Week 6
Group
Value
95% CI
IDP-122 Lotion
30.14
IDP-122 Vehicle Lotion
7.93
Week 12
Group
Value
95% CI
IDP-122 Lotion
19.48
IDP-122 Vehicle Lotion
6.69
Adverse events — posted to ClinicalTrials.gov
Time frame: Baseline through Week 12.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT02515097 — Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
· Phase 3
· completed
Other recruiting trials for Plaque Psoriasis
Currently open trials in the same condition.
NCT07357831 — A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psor
· Phase 3
· recruiting
NCT07250802 — A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
· Phase 3
· recruiting
NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit
· Phase 3
· recruiting
NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
· NA
· recruiting
NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
· Phase 3
· recruiting
Other Bausch Health Americas, Inc. trials
Trials by the same sponsor.
NCT07285785 — Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
· Phase 4
· recruiting
NCT07428538 — Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
· Phase 3
· recruiting
NCT05098028 — Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease
· Phase 2
· completed
NCT05027282 — Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatm
· NA
· completed
NCT05132231 — Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Wor
· active not recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bausch Health Americas, Inc.
Last refreshed: 27 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02514577.